Umeclidinium

Drug Profile

Umeclidinium

Alternative Names: 573719; Ellipta Incruse; Encruse Ellipta; GSK-573719; Incruse; Incruse Ellipta; UMEC; Umeclidinium bromide

Latest Information Update: 07 Jan 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Benzhydryl compounds; Bronchodilators; Quinuclidines; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Phase II Hyperhidrosis
  • Discontinued Asthma

Most Recent Events

  • 01 Dec 2016 GlaxoSmithKline completes a phase II trial for Hyperhidrosis in USA and Canada (Topical) (NCT02673619)
  • 20 Sep 2016 GlaxoSmithKline plans a phase IV trial for Chronic obstructive pulmonary disease in Australia (Inhalation) (ACTRN12616001208493)
  • 28 Jul 2016 GlaxoSmithKline does not wish to exercise the option to take a licence to any additional patents and option agreement for Ellipta® products under the worldwide non-exclusive agreement with Vectura
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top